A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC

by | Jul 29, 2026 | Clinical Trials | 0 comments

​ Conditions: Advanced Esophageal Squamous Cell Carcinoma; Metastatic Esophageal Squamous Cell Carcinoma

Interventions: Drug: Tislelizumab; Drug: Oxaliplatin; Drug: Leucovorin; Drug: 5-fluorouracil (5-FU)

Sponsors: BeOne Medicines

Not yet recruiting Conditions: Advanced Esophageal Squamous Cell Carcinoma; Metastatic Esophageal Squamous Cell Carcinoma
Interventions: Drug: Tislelizumab; Drug: Oxaliplatin; Drug: Leucovorin; Drug: 5-fluorouracil (5-FU)
Sponsors: BeOne Medicines
Not yet recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *